TUMOR-ASSOCIATED DENDRITIC CELL PREPARATIONS AND USES THEREOF
20190054116 ยท 2019-02-21
Inventors
- Jo Van Ginderachter (Ninove, BE)
- Damya Laoui (Limal, BE)
- Jiri Keirsse (Bornem, BE)
- Martin Guilliams (Blaasveld, BE)
Cpc classification
A61K35/15
HUMAN NECESSITIES
A61K2039/5154
HUMAN NECESSITIES
C12N5/0639
CHEMISTRY; METALLURGY
International classification
A61K35/15
HUMAN NECESSITIES
A61K39/00
HUMAN NECESSITIES
Abstract
The present application relates to tumor-associated dendritic cell (TADC) preparations and their use in treatment of tumor metastasis.
Claims
1. A method of treating tumor metastasis in a subject, the method comprising: administering to the subject a composition comprising an isolated tumor-associated dendritic cell (TADC) subset of pre-conventional dendritic cell (pre-cDC) origin, wherein the composition is essentially devoid of monocyte-derived dendritic cells (Mo-DCs), and wherein the TADC subset was obtained from a resected tumor or a resected tumor-draining lymph node of a mammal.
2. The method according to claim 1, wherein the composition comprises no more than 1% Mo-DCs.
3. The method according according to claim 1, wherein the TADC subset has the characteristic cell surface phenotype of at least CD16 CD11c+ HLA-DR+ BDCA2 CD14.
4. The method according to claim 3, wherein the TADC subset is further characterized as BDCA1 BDCA3+ CD11b.
5. The method according to claim 3, wherein the TADC subset is further characterized as BDCA1+ BDCA3 CD11b+.
6. The method according to claim 1, further comprising: isolating TADCs from a resected tumor or a resected tumor-draining lymph node of a mammal, and enriching TADC subsets in a manner effective to obtain a population essentially devoid of Mo-DCs
7. The method according to claim 1, wherein enriching includes one or more of buoyant density centrifugation, magnetic-activated cell sorting (MACS), and fluorescently activated cell sorting (FACS).
8. A pharmaceutical composition comprising: an isolated tumor-associated dendritic cell (TADC) subset of pre-conventional dendritic cell (pre-cDC) origin, wherein the composition is essentially devoid of monocyte-derived dendritic cells (Mo-DCs), and wherein the TADC subset was obtained from a resected tumor or a resected tumor-draining lymph node of a mammal.
9. (canceled)
10. The method isolating a tumor-associated dendritic cell (TADC) subset, the method comprising: isolating TADCs from a resected tumor or a resected tumor-draining lymph node of a mammal, and enriching TADC subsets in a manner effective to obtain a population essentially devoid of Mo-DCs.
Description
BRIEF DESCRIPTION OF DRAWINGS
[0014]
[0015]
[0016]
[0017]
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
DETAILED DESCRIPTION
[0027] The present invention will be described with respect to particular embodiments and with reference to certain drawings but the invention is not limited thereto but only by the claims. Any reference signs in the claims shall not be construed as limiting the scope. The drawings described are only schematic and are non-limiting. In the drawings, the size of some of the elements may be exaggerated and not drawn on scale for illustrative purposes. Where the term comprising is used in the present description and claims, it does not exclude other elements or steps. Where an indefinite or definite article is used when referring to a singular noun e.g. a, an or the, this includes a plural of that noun unless something else is specifically stated.
[0028] Furthermore, the terms first, second, third and the like in the description and in the claims, are used for distinguishing between similar elements and not necessarily for describing a sequential or chronological order. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operation in other sequences than described or illustrated herein.
[0029] The cell surface markers included in this invention may refer to human cell surface markers or any orthologous cell surface markers that are functionally equivalent. Therefore, cell surface markers may also refer to e.g. but not limited to mouse cell surface markers.
[0030] The following terms or definitions are provided solely to aid in the understanding of the invention. Unless specifically defined herein, all terms used herein have the same meaning as they would to one skilled in the art of the present invention. Practitioners are particularly directed to Sambrook et al., Molecular Cloning: A Laboratory Manual, 2.sup.nd ed., Cold Spring Harbor Press, Plainsview, N.Y. (1989); and Ausubel et al., Current Protocols in Molecular Biology (Supplement 47), John Wiley & Sons, New York (1999), for definitions and terms of the art. The definitions provided herein should not be construed to have a scope less than understood by a person of ordinary skill in the art.
[0031] A dendritic cell or DC is an APC that typically expresses the MHC class II cell surface antigen HLA-DR (human leukocyte antigen DR) and co-stimulatory molecules, and lacks expression of (or has low expression of) markers specific for granulocytes, NK cells, B lymphocytes, and T lymphocytes. DCs are able to initiate antigen specific primary T lymphocyte responses in vitro and in vivo, and direct a strong mixed leukocyte reaction (MLR) compared to peripheral blood leukocytes, splenocytes, B cells and monocytes. Generally, DCs ingest antigen by phagocytosis or pinocytosis, degrade it, present fragments of the antigen at their surface and secrete cytokines.
[0032] A tumor-associated dendritic cell or TADC is a DC derived from a tumor microenvironment.
[0033] A pre-conventional DC or pre-cDC, as used herein, is a hematopoietic precursor cell derived from the bone marrow and committed to the DC lineage, whereas said pre-cDC is distinct from monocytes and monocyte-derived DCs and whereas said pre-cDC is a partially differentiated cell having the capacity of undergoing further differentiation into conventional DCs.
[0034] A conventional DC or cDC is a fully differentiated DC derived from a pre-cDC precursor cell. cDCs are characterized by the cell surface phenotype of at least CD16 CD11c+ HLA-DR+ BDCA2 and CD14.
[0035] A monocyte-derived dendritic cell or Mo-DC is a cell derived from peripheral blood monocytes and characterized by expression of at least HLD-DR, CD11c, BDCA1, CD11b and CD14.
[0036] A TADC subset essentially devoid of monocyte-derived dendritic cells (Mo-DCs), as used herein, is an essentially pure TADC subset that may include unavoidable levels of impurities of Mo-DCs but no more. This means that the TADC subset is essentially pure and comprises no more than 1% Mo-DCs. For instance, essentially devoid of Mo-DCs can mean 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1% or less Mo-DCs. It can also mean 0% Mo-DCs, referring to a lack of a detectable amount of Mo-DCs.
[0037] The term isolated, as used herein, means having been removed from its natural environment. Isolated does not require absolute isolation; rather, it is intended as a relative term. Thus, for example, an isolated cell subset is one in which said cell subset is more pure than the cell subset in its natural environment within a tissue.
[0038] The term enriched, as used herein, means having increased the purity of a cell type or cell subset within a cell population. Enriched does not require absolute enrichment; rather, it is intended as a relative term. Thus, for example, an enriched cell subset is one in which said cell subset is more pure than the purity of said cell subset before enrichment.
[0039] As used herein, the term BDCA3+ or BDCA3 positive refers to a characteristic cell surface phenotype and means that cells are immunoreactive with antibodies specific to BDCA3, i.e. the results of a flow cytometry analysis of cells stained with a fluorescently labeled anti-BDCA3 antibody indicate a shift in fluorescence intensity compared to the same cells stained with an isotype control antibody, using the same procedure. Such cells are said to express BDCA3 on the cell surface. Likewise, BDCA3- or BDCA3 negative means the cells are not immunoreactive with antibodies specific to BDCA3, i.e. the results of a flow cytometry analysis of cells stained with a fluorescently labeled anti-BCDA3 antibody indicate no detectable shift in fluorescence intensity compared to the same cells stained with an isotype control antibody, using the same procedure. Such cells are said to not express BDCA3 on the cell surface. The same applies to the surface expression of BDCA1, BDCA2, CD11b, CD11c, CD14, CD16 and HLA-DR. BDCA1+ cells are said to express BDCA1 on the cell surface, whereas BDCA1 cells are said to be negative for BDCA1 cell surface expression. BDCA2 cells are said to be negative for BDCA2 cell surface expression. CD11b+ cells are said to express CD11b on the cell surface, whereas CD11b cells are said to be negative for CD11b cell surface expression. CD11c+ cells are said to express CD11c on the cell surface. CD14 cells are said to be negative for CD14 cell surface expression. CD16 cells are said to be negative for CD16 cell surface expression and HLA-DR+ cells are said to express HLA-DR on the cell surface. In the present invention the cell surface phenotype is characterized by the presence or absence of surface cell markers. The mentioned surface cell markers represent human markers. Included in this invention are nevertheless also orthologous markers that are functionally equivalent to the mentioned human markers.
[0040] Mammal, as used herein, refers to any member of the class Mammalia, including, without limitations, humans and nonhuman primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats, lamas and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats, and guinea pigs, and the like. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be included within the scope of this term. The terms patient, individual and subject are used interchangeably herein, and cover mammals including humans.
[0041] Tumor or tumor tissue, as used herein, refers to all cells with neoplastic cell growth and proliferation, whether malignant or benign, and to tumor-associated cell. Tumor refers to the tumor tissue as a whole, including different cell types that are present in the tumor environment. Tumor tissue includes cancer cells but also non-transformed host cells, or tumor-associated cells, such as tumor-associated stroma cells. Examples of tumor-associated cells include TADCs and tumor-associated macrophages (TAMs). Tumor may be any type of cancer including but not limited to solid tumors. A solid tumor may be a cancerous tumor including, but not limited to, the ones occurring in the mammals prostate, stomach, liver, spleen, pancreas, colon, kidney, gall bladder, ovary, testicle, penis, rectum, lung, trachea, breast, heart, brain, thyroid, parathyroid, pituitary, thymus, muscle, head, neck, skin, retina, uvea, conjunctiva, salivary gland, adrenal gland, throat, esophagus, sweat glands and sebaceous glands.
[0042] A resected tumor, as used herein refers to a tumor that was previously surgically removed. Resection may refer to the surgical removal of all of the cancerous tissue that is visible. A resected tumor is therefore obtained post-surgically, i.e. after the tumor is removed by surgery. Tumor resection includes resection of primary and secondary tumors. Resection may also refer to the removal of part of the tumor, by methods such as but not limited to biopsy. The partly resected tumor is therefore obtained post-surgically, i.e. after part of the tumor is removed by biopsy.
[0043] A resected tumor-draining lymph node, as used herein refers to a tumor-draining lymph node that was previously surgically removed. Surgical removal can refer to lymphadenectomy, which means lymph node dissection of one or more groups of lymph nodes. Surgical removal can also refer to biopsy.
[0044] Metastasis, as used herein refers to the process in which cancer cells originating in one organ or part of the body relocate to another part of the body and continue to replicate. Metastasized cells can subsequently form tumors which might further metastasize. Metastasis thus refers to the spread of cancer, from the part of the body where it originally occurred, to other parts of the body.
[0045] Treatment and treating, as used herein refer to both therapeutic treatment and prophylactic or preventative measures, wherein the objective is to inhibit or slow down (lessen) the targeted disorder (e.g. cancer) or symptom of the disorder, or to improve a symptom, even if the treatment is partial or ultimately unsuccessful. Those in need of treatment include those already diagnosed with the disorder as well as those prone or predisposed to contract the disorder or those in whom the disorder is to be prevented. For example, in tumor (e.g. cancer) treatment, a therapeutic agent can directly decrease the pathology of tumor cells, or render the tumor cells more susceptible to treatment by other therapeutic agents or by the subject's own immune system.
[0046] A first aspect of the present invention relates to an isolated TADC subset of pre-cDC origin, essentially devoid of Mo-DCs, wherein said TADC subset is obtained from a resected tumor or a resected tumor-draining lymph node of a mammal, for use in treatment of tumor metastasis in said mammal. Therefore, specific embodiments of the isolated TADC subset include (a) the derivation of said TADC subset from pre-cDCs, (b) the virtual absence of Mo-DCs and (c) the collection of the TADC subset from a tumor or a tumor-draining lymph node after resection of said tumor or tumor-draining lymph node. An isolated TADC subset of pre-cDC origin, as used herein, can mean one or more TADC subsets of pre-cDC origin. Preferably, said TADC subset comprises one TADC subset. Alternatively, said TADC subset may comprise several TADC subsets/a mix of TADC subsets of pre-cDC origin. The tumor-derived DC subsets of interest may be from a resected tumor or a resected tumor-draining lymph node, whereas the isolation of the TADC subset from said tissues is done after surgical resection of the tumor or tumor-draining lymph node. In a preferred embodiment, the TADCs of interest include cells of mammalian origin, more preferably of human origin.
[0047] TADC subsets may be isolated, for example, by standard isolation techniques. In some embodiments, the TADC subsets may be isolated from the resected tumor or from the resected tumor-draining lymph node by preparation of a tumor single cell suspension. In a specific embodiment, such tumor single cell suspension may be obtained by cutting the resected tumor or the resected tumor-draining lymph node in small pieces, incubation of said pieces with digestion medium comprising collagenases and DNases, followed by density gradient centrifugation to remove cell debris and dead cells. A non-limiting example of a technique for isolation of TADCs and/or TADC subsets can be found in Laoui et al., 2014, hereby incorporated by reference.
[0048] TADC subsets, e.g. from tumor single cell suspensions, may be enriched, for example, by MACS and/or FACS. In some embodiments, a TADC subset is enriched such that the tumor-derived DC subset represents at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% of the total cell content of the cell preparation. According to the invention, the isolated TADC subset is essentially devoid of Mo-DCs. The TADC subset as described above may contain several TADC subsets, i.e. a mix of TADC subsets. In some embodiments, a mix of TADC subsets is enriched such that the mix of tumor-derived DC subsets represents at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% of the total cell content of the cell preparation. According to the invention, the isolated mix of TADC subsets is essentially devoid of Mo-DCs. In some embodiments, the different TADC subsets may be enriched separately and mixed after enrichment. In alternative embodiments, the different TADC subsets may be enriched in the same enrichment procedure.
[0049] According to particular embodiments, the TADC subset as described herein above comprises 1% or less Mo-DCs, i.e. the isolated subset does not contain more than 1% Mo-DCs. The level of contamination typically will be evaluated by flow cytometry analysis.
[0050] According to particular embodiments, the isolated TADC subset as described above is characterized by a phenotype that is positive for the MHC class II cell surface antigen HLA-DR) and surface antigen CD11c and negative for surface antigens CD16, BCDA2 and CD14. In further particular embodiments, said TADC subset is further characterized by a phenotype that is positive for surface antigen BDCA3 (blood dendritic cell antigen 3) and negative for surface antigens BDCA1 (blood dendritic cell antigen 1) and CD11b. Said TADC subset, with the cell surface phenotype CD16 CD11c+ HLA-DR+ BDCA2 CD14 BDCA1 BDCA3+ CD11b, is herein further called cDC1 subset.
[0051] According to particular embodiments, the isolated TADC subset as described above is characterized by a phenotype that is positive for the MHC class II cell surface antigen HLA-DR and surface antigen CD11c and negative for surface antigens CD16, BCDA2 and CD14 and further characterized by a phenotype that is negative for surface antigen BDCA3 and positive for surface antigens BDCA1 and CD11b. Said TADC subset, with the cell surface phenotype CD16 CD11c+ HLA-DR+ BDCA2 CD14 BDCA1+ BDCA3 CD11b+, is herein further called cDC2 subset. BDCA3 and interferon regulatory factor 8 (IRF8) are equivalently good markers to define the cDC1 subset versus the cDC2 subset and can be used interchangeably.
[0052] According to specific embodiments, said cDC1 subset is particularly useful for treating metastasis in a mammal having cancer. In further particular embodiments, the cDC1 subset may be used for treating metastasis in mammals having tumors that are sensitive to cytotoxic T lymphocytes (CTLs). Non-limiting examples of such CTL-sensitive tumors include melanoma, non-small cell lung carcinoma (NSCLC), colon carcinoma and microsatellite instable tumors such as uro-digestive tumors.
[0053] According to specific embodiments, said cDC2 subset is particularly useful for treating metastasis in a mammal having cancer. In further particular embodiments, the cDC2 subset may be used for treating metastasis in mammals having tumors with a strong immunosuppressive myeloid compartment. A non-limiting example of a tumor with a strong immunosuppressive myeloid compartment is breast carcinoma.
[0054] According to a specific embodiment, the TADC subsets as described above may be obtained by a procedure which includes (a) the preparation of TADCs from a previously resected tumor or tumor-draining lymph node of a mammal and (b) the purification of TADC subsets from said TADC preparation, in order to achieve a TADC sub-population that is almost devoid of Mo-DCs. According to particular embodiments, said procedure may employ buoyant density centrifugation, immunomagnetic selection and/or depletion and fluorescently activated cell sorting (FACS). Those methods are non-limiting and can be combined. It should be noted that any of a variety of isolation methods known to those of skill in the art may be used to achieve enrichment of the TADC subset, examples of which are provided above.
[0055] The present invention pertains to pharmaceutical compositions comprising the TADC subset described herein, also referred to as active ingredient, and a pharmaceutically acceptable carrier or excipient for use in treatment of tumor metastasis. These compositions can be utilized to achieve the desired pharmacological effect by administration to a subject in need thereof. A pharmaceutically acceptable carrier is preferably a carrier that is relatively non-toxic and innocuous to a subject at concentrations consistent with the effective amount of the active ingredient so that any side effects ascribable to the carrier do not vitiate the beneficial effects of the active ingredient. A pharmaceutically effective amount of the active ingredient is preferably that amount which produces a result or exerts an influence on the particular condition being treated. Typically said pharmaceutical compositions may comprise one TADC subset. Said pharmaceutical compositions may comprise several/a mix of TADC subsets.
[0056] The present invention also provides a method of treating tumor metastasis in a mammal, wherein the method comprises the administration of an isolated TADC subset, which was obtained from the same mammal, and which is further characterized as (a) originating from pre-cDCs, (b) lacking Mo-DCs, and (c) being isolated from a previously resected tumor or tumor-draining lymph node.
[0057] The isolated TADC subset or the pharmaceutical composition comprising the TADC subset of the present invention can be used to treat metastasis of cancer such as but not limited to melanoma. In particular embodiments, the isolated TADC subset cDC1 or the pharmaceutical composition comprising the TADC subset cDC1 can be used to treat CTL-sensitive tumors, such as but not limited to melanoma, NSCLC, colon carcinoma and microsatellite instable tumors.
[0058] In other embodiments the isolated TADC subset cDC2 or the pharmaceutical composition comprising the TADC subset cDC2 can be used to treat tumors that are characterized by the presence of a high amount of immunosuppressive myeloid cells, such as but not limited to breast carcinoma.
[0059] In various embodiments, the isolated TADC subset or the pharmaceutical composition comprising the TADC subset are administered in an amount sufficient to induce an immune response against the antigens (e.g. a T cell response). Other embodiments of the present invention provide for methods of treating cancers (e.g. melanoma, breast cancer) using the isolated TADC subset as described above or the pharmaceutical composition comprising the TADC subset as described above. In one embodiment, the method of treating cancer comprises administering an isolated TADC subset or the pharmaceutical composition comprising the TADC subset as described herein to a mammal. In one embodiment, the method of treating cancer comprises administering an isolated TADC subset or the pharmaceutical composition comprising the TADC subset as described herein to a human patient. Other embodiments provide for methods of treating metastasis of cancers such as melanoma, NSCLC, colon carcinoma, microsatellite instable tumors or breast cancer. In one embodiment, the isolated TADC subset or the pharmaceutical composition comprising the TADC subset can comprise autologous DCs. DCs suitable for use in the vaccination methods disclosed herein can be isolated or obtained from the tumor tissue in which such cells are found.
[0060] The isolated TADC subset or the pharmaceutical composition comprising the TADC subset can be administered in conjunction with other therapeutic treatments; for example, including but not limited to, chemotherapy, immunotherapy and/or radiation. The isolated TADC subset or the pharmaceutical composition comprising the TADC subset can be administered by injection via the intradermal, intra-arterial, subcutaneous, intramuscular, intravenous, intralymphatic or intranodal routes. In other embodiments, the inventive isolated TADC subset or the pharmaceutical composition comprising the TADC subset are administered directly into or in close proximity of the tumor or directly into or in close proximity of the site of the resected tumor. The isolated TADC subset or the pharmaceutical composition comprising the TADC subset can be administered one or more times to a mammal to impart beneficial results. The isolated TADC subset or the pharmaceutical composition comprising the TADC subset can be administered post-surgically, i.e. after resection of the tumor. One skilled in the art will be able to determine the appropriate timing for administering the isolated TADC subset or the pharmaceutical composition comprising the TADC subset. The timing of the first and/or subsequent dose(s) of the isolated TADC subset or the pharmaceutical composition comprising the TADC subset can depend on a variety of factors, including, but not limited to a mammals health, stability, age, and weight. The isolated TADC subset or the pharmaceutical composition comprising the TADC subset can be administered at any appropriate time interval; for example, but not limited to, once per week, once every two weeks, once every three weeks, once per month. In one embodiment, the isolated TADC subset or the pharmaceutical composition comprising the TADC subset can be administered indefinitely. In one embodiment, the isolated TADC subset or the pharmaceutical composition comprising the TADC subset can be administered three times in two week intervals. The isolated TADC subset or the pharmaceutical composition comprising the TADC subset can be prepared and frozen for later use or the isolated TADC subset or the pharmaceutical composition comprising the TADC subset can be prepared for immediate use. Appropriate dosages of the isolated TADC subset or the pharmaceutical composition comprising the TADC subset depends on a variety of factors, including, but not limited to, a mammals health, stability, age, and weight. In one embodiment, the isolated TADC subset or the pharmaceutical composition comprising the TADC subset includes from about 10.sup.4 to about 10.sup.6 TADCs. In another embodiment, the isolated TADC subset or the pharmaceutical composition comprising the TADC subset includes about 10.sup.6 to about 10.sup.7 TADCs. In another embodiment, the isolated TADC subset or the pharmaceutical composition comprising the TADC subset includes about 10.sup.7 TADCs.
[0061] According to a further aspect, a pharmaceutical composition is provided comprising the TADC subset of pre-cDC origin and essentially pure regarding the presence of Mo-DCs, wherein said TADC subset is obtained post-surgically from a resected tumor or tumor-draining lymph node. It is envisaged herein that the pharmaceutical composition is provided for the treatment of tumor metastasis in a mammal. Said mammal is the same mammal from which the TADC subset was isolated.
[0062] In another aspect, a method of treating tumor metastasis in a mammal is provided, the method comprising the administration of a TADC subset or a pharmaceutical composition comprising said TADC subset to said mammal, whereas (a) the TADC subset derives from pre-cDCs, (b) the TADC subset does not contain Mo-DCs, (c) the TADC subset is isolated from a resected tumor or a resected tumor-draining lymph node.
[0063] It is to be understood that although particular embodiments, specific configurations as well as materials and/or molecules, have been discussed herein for cells and methods according to the present invention, various changes or modifications in form and detail may be made without departing from the scope and spirit of this invention. The following examples are provided to better illustrate particular embodiments, and they should not be considered limiting the application. The application is limited only by the claims.
EXAMPLES
Materials and Methods to the Examples
Mice, Cell Lines and Tumor Models
[0064] Female Balb/c, CD45.2 and CD45.1 C57BL/6 mice were from Janvier. Ubiquitin-GFP mice were purchased from Jackson. Csf2rb.sup./, Flt3l.sup./, Ccr2.sup./ and MMTV-PyMT mice were provided by Melanie Greter (University of Zurich, Germany), Bart Lambrecht (UGent, Belgium), Frank Tacke (Aachen University, Germany) and Massimiliano Mazzone (KULeuven, Belgium) respectively. All procedures followed the guidelines of the Belgian Council for Laboratory Animal Science.
[0065] LLC was purchased from the ATCC cell biology collection. 3LL-R and 3LL-S cells were generated in house from C57BL/6 Lewis Lung carcinoma as previously described (Remels and De Baetselier, 1987). LLC-OVA, MC38, B16-OVA and T241 cells were kind gifts of Dmitry Gabrilovich (The Wistar Institute, Philadelphia, USA), Massimiliano Mazzone (VIB-KULeuven, Leuven, Belgium), Karine Breckpot (Vrije Universiteit Brussel, Brussels, Belgium) and Lena Claesson-Welsh (University of Uppsala, Uppsala, Sweden) respectively.
[0066] LLC-OVA, 3LL-R and 3LL-S cell lines were maintained in Roswell Park Memorial Institute-1640 medium (RPMI; Sigma) supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS; Gibco), 300 g/ml L-glutamine (Gibco), 100 units/ml penicillin and 100 g/ml streptomycin (Gibco) and monthly tested for the presence of mycoplasma. For MC38, B16-OVA and T241 cultures, RPMI was replaced by Dulbecco's Modified Eagle Medium (DMEM, Sigma). LLC, LLC-OVA, 3LL-R, 3LL-S lung carcinoma cells, MC38 colon carcinoma cells, B16-OVA melanoma cells and T241 ficrosarcoma cells were harvested and single cell suspensions of 310.sup.6 in 200 l of PBS were injected subcutaneously into the right flank of syngeneic C57BI/6 mice. Female MMTV-PyMT mice develop mammary tumors spontaneously.
[0067] For ex-vivo TADC and T-cell cultures, this medium was supplemented with 1 mM non-essential amino acids (Invitrogen), 1 mM sodium pyruvate (Invitrogen) and 0.02 mM 2-mercapto ethanol (Invitrogen).
[0068] For intrathoracic 3LL-R injections, 510.sup.5 3 LL-R carcinoma cells were harvested and resuspended together with 25 g Matrigel in 50 l PBS. Cell suspensions were kept on ice until injection. Mice were anesthetized and placed in the left lateral decubitus position. One-ml tuberculin syringes with 30-gauge hypodermic needles were used to inject the cell inoculum percutaneously into the right lateral thorax, at the lateral dorsal axillary line, approximately 1.5 cm above the lower rib line just below the inferior border of the scapula. The needle was quickly advanced 6 mm into the thorax and was quickly removed after the injection. After tumor injection, the mouse was turned to the right lateral decubitus position. At day 7, mice were sacrificed and lung tissue and lung tumors were removed.
[0069] For trans-anal rectal cancer injections, mice were anesthetized with a 1/10 Nembutal dilution. The anal orifice was gently enlarged with a blunt-tipped forceps. In case of feces present, the colon was rinsed with saline using a flexible catheter. MC38 cells were injected submucosally into the distal posterior rectum at concentrations of 2.510.sup.5 per 50 l PBS with a 29-gauge syringe. After the injection, the syringe was kept in position for a few seconds, to prevent back flow. After 4 weeks, mice were sacrificed and tumors were carefully removed.
[0070] Tumor volumes were determined by caliper measurements and calculated using the formula: V=[d.sup.2D]/6, where d is the minor tumor axis and D is the major tumor axis. Lung cancer and colorectal cancer patients
[0071] We enrolled four non-small-cell lung carcinoma (NSCLC) patients that were not subjected to neo-adjuvant chemotherapy, including 2 males (68 and 67 years of age) with pT2aN1M0 (stage IIA) spinocellular carcinoma and cT1bN0M0 (stage IA) carcinoma and 2 females (67 and 59 years of age) with pT2aN0M0 (stage IB) adenocarcinoma and pT2aN1M0 (stage IIA) spinocellular carcinoma. The four colorectal cancer patients enrolled were not subjected to chemotherapy and included 3 males (71 and 62 years of age) with pT3N0 adenocarcinomas, one male with (79 years of age), with stage I T2MONO adenocarcinoma, and one female (49 years of age) with stage IV adenocarcinoma. All protocols were approved by the Ethics Committee of the University Hospitals Gasthuisberg (Leuven, Belgium), and all subjects gave written informed consent before study participation.
Tumor, Lymph Node, Bone Marrow and Spleen Preparation, Flow Cytometry and Cell Sorting
[0072] Tumors were excised, cut in small pieces, treated with 10 U/mL collagenase I, 400 U/mL collagenase IV, and 30 U/mL DNasel (Worthington) for 30 min at 37 C., squashed and filtered. Red blood cells were removed using erythrocyte lysis buffer and density gradients (Axis-Shield) were used to remove debris and dead cells.
[0073] Tumor-draining lymph nodes (LN) were cut, dissociated with 10 U/mL collagenase I, 400 U/mL collagenase IV, and 30 U/mL DNasel (Worthington) for 45 min at 37 C. and filtered.
[0074] Spleens were flushed with 200 U/mL collagenase III (Worthington) and left for 30 min at 37 C. Afterwards, spleens were filtered and red blood cells were removed using erythrocyte lysis buffer.
[0075] To purify DC subpopulations from tumor, spleen or LN, CD11c+ cells were MACS-enriched (antiCD11c microbeads, Miltenyi) and sorted using a BD FACSAria II (BD Biosciences).
[0076] Bone marrow (BM) leukocytes were isolated through flushing of tibia and femur. The obtained cell suspensions were filtered, red blood cells were removed using erythrocyte lysis buffer. To purify BM monocytes, CD11b.sup.+ cells were MACS-enriched (antiCD11b microbeads, Miltenyi) before sorting.
[0077] Commercial antibodies for cell surface stainings are listed in Table 1. To prevent aspecific binding, cells were pre-incubated with rat anti-mouse CD16/CD32 (clone 2.4G2, BD Biosciences).
[0078] Normalized delta-Median Fluorescence Intensity (MFI) was calculated as: [(MFI staining)(MFI isotype staining)]/(MFI staining). FACS data were acquired using a BD FACSCanto II or LSRII (both from BD Biosciences) and analyzed using FlowJo (Tree Star, Inc.). To purify TADC, cells were sorted using a BD FACSAria II (BD Biosciences) from 9-15 pooled tumors.
Measurement of Cytokine and Chemokine Production
[0079] Cytokine and chemokine concentrations were measured by Bio-Plex (Bio-Rad), according to the supplier's protocols.
In Vitro and In Vivo Phagocytosis, DQ-OVA Processing, Mixed Leukocyte Reaction Assays and OT-I and OT-II T-Cell Activation
[0080] For in vitro latex uptake, freshly isolated tumor single-cell suspensions were cultured in 96-well plates for 40 minutes at 4 C. or 37 C., in the presence of latex microspheres (Polysciences) diluted at 1:5000. Latex uptake by TADC was assessed via flow cytometry. For measuring in vivo latex uptake by TADC, tumor-bearing mice were injected IV with 250 l of yellow-green latex microspheres (Polysciences) diluted 1:25 in PBS. 1-2 hours later, tumor single cell suspensions were made and latex uptake by TADC subpopulations was assessed via flow cytometry.
[0081] To assess TADC antigen processing, tumor single cell suspensions were incubated for 15 minutes at 0 C. or 37 C. in the presence of 10 g/ml DQ-OVA (Molecular Probes), allowing antigen uptake. After thorough washing, cells could further process DQ-OVA intracellularly during different time intervals, at 0 C. or 37 C. Following each time interval, cells were surface labeled and DQ-OVA fluorescence in each subset was measured via flow cytometry.
[0082] For OT-I and OT-II proliferation assays, MACS sorted CD11c.sup.CD8.sup.+ OT-1 and CD11c.sup.CD4.sup.+ OT-2 T cells were stained with 0.2 M CFSE (Molecular Probes, Carlsbad, Calif., USA) following the manufacturer's instructions. Purified TADC were added to 10.sup.5 OT-I or OT-II T cells and stimulated with 1 g/ml anti-CD3 and 2 g/ml CD28 for a positive control. To inhibit iNOS the cocultures were supplemented with 5 M L-NMMA (NG-monomethyl-L-arginine, Alexis Biochemicals). After 72 h of co-incubation, proliferation of T cells was measured via CFSE dilution using flow cytometry.
Adoptive Pre-cDC and Monocyte Transfers
[0083] Bone marrow Ly6C.sup.hi monocytes and pre-cDC were labeled with CellTrace (life technologies) and sorted from CD45.2 mice. 10.sup.6 Ly6C.sup.hi monocytes or 410.sup.5 pre-cDC were intravenously injected in 3LL-R tumor-bearing CD45.1 mice. The fate of the CD45.2.sup.+ CellTrace.sup.+ progeny was determined 72 hours later.
TADC Vaccination Experiments
[0084] For vaccination experiments naive C57BI/6 mice were subcutaneously injected with 10.sup.4 TADC of a specific subset, 6 and 3 weeks prior to subcutaneous LLC-OVA or B16-OVA inoculation. TADC were sorted from a pool of 10 to 12 LLC-OVA tumor bearing-mice or B16-OVA tumor bearing-mice. Mice vaccinated subcutaneously with 100 g OVA protein in 100l CFA were used as positive controls.
RNA Extraction, cDNA Preparation and Quantitative Real-Time PCR
[0085] These experiments were performed as described before (Movahedi et al., 2010). RNA was extracted using TRIzol (Invitrogen) and was reverse-transcribed with oligo(dT) and SuperScript II RT (Invitrogen). Quantitative real-time PCR was performed in an iCycler, with iQ SYBR Green Supermix (Bio-Rad). Primer sequences are listed in Supplementary Table 2. PCR cycles consisted of 1 94 C., 45 55 C., 1 72 C. Gene expression was normalized using ribosomal protein S12 (Mrps12) as a housekeeping gene. Primers are listed in Table 2. Statistics
[0086] Significance was determined by the Student's t test or ANOVA followed by a post test using GraphPad Prism 6.0 software. A p-value <0.05 was considered statistically significant. All graphs show meanSEM.
Example 1. Distinct Tumor-Associated Dendritic Cell Subpopulations Derive from Different Precursors
[0087] To delineate the relative abundance of distinct tumor-associated DC (TADC) populations in solid tumors, we first employed the 3LL-R Lewis Lung Carcinoma model which is known to be strongly infiltrated by myeloid cells (Laoui et al., 2014). These tumors contain a sizeable population of CD3.sup.neg CD19.sup.neg Ly6G.sup.neg CD11C.sup.hi MHC-II.sup.hi TADC (
[0088] We further assessed the origin of TADC subsets by adoptive transfer of pre-cDCs and monocytes in 3LL-R tumor-bearing mice. When adoptively transferring sorted CD45.2.sup.+ B220.sup. CD11c.sup.+ Sirp.sup.int CellTrace.sup.+ bone marrow pre-cDC precursors (Scott et al., 2015) in 3LL-R tumor-bearing CD45.1.sup.+ recipient mice, only Ly6C.sup.lo CD64.sup.lo CD24.sup.+ CD11b.sup.lo and Ly6C.sup.lo CD64.sup.lo CD24.sup.int-lo CD11b.sup.+ cells could be retrieved from tumors after 72 h (
[0089] Corroborating the adoptive transfer experiments, 3LL-R tumors grown in CCR2-deficient mice, in which the egression of monocytes from the BM is strongly reduced (Serbina et al., 2008), showed almost complete absence of the Mo-DC subset while cDC1 and cDC2 were unaffected (
[0090] Following the fate mapping experiments, we further characterized the TADC subsets for markers that were reported to associate with different DC populations. In this respect, the need for IRF8 and IRF4 in the development of cDC1 and cDC2, respectively, has been established (Tamura et al., 2005). Intracellular staining for these transcription factors confirmed the higher expression of IRF4 in cDC2 and of IRF8 in cDC1 (
Example 2: Distinct Tumor-Associated Dendritic Cell Subpopulations are Present in Multiple Tumor Types
[0091] We then assessed the presence of TADC subsets in several transplantable mouse tumor models of various histological origins and distinct genetic backgrounds and in the spontaneous MMTV-PyMT breast carcinoma model. Single cell suspensions of subcutaneously growing LLC lung carcinoma tumors, their fast progressing 3LL-R and slowly progressing 3LL-S subclones (Remels and De Baetselier, 1987), MC38 colon carcinoma, B16 melanoma and T241 fibrosarcoma, as well as 3LL-R tumors orthotopically growing in the lung parenchyma and MC38 orthotopically growing in the rectum (all in C57BI/6 background) contained small, but clearly identifiable CD11c.sup.hi MHC-II.sup.hi TADC fractions (
[0092] When comparing the DC content of similarly sized tumors, the cDC1 were the rarest subset in all investigated models, whereas the cDC2 were always well represented (between 30.1% and 75.7% of all TADC depending on the model) (
Example 3: The Presence of Distinct Tumor-Associated Dendritic Cell Subpopulations can be Recapitulated in Human Tumors
[0093] To translate our original findings to the human situation, the presence of distinct TADC subpopulations was assessed in fresh tumor biopsies of lung and colorectal cancer patients. Small amounts of CD16.sup. CD11c.sup.+ HLA-DR.sup.+ TADC were retrieved from human tumors (
Example 4: Mo-DC have the Highest Inherent Antigen Uptake and Processing Capacities
[0094] Although the induction of potent anti-tumor immune responses has been attributed to DCs in some reports (Goc et al., 2014; Preynat-Seauve et al., 2006), TADC have also been described as tolerogenic or immunosuppressive cells with impaired antigen presenting, T-cell stimulating and migratory capacities, enabling tumor immune escape (Gabrilovich, 2004; Ma et al., 2013; Preynat-Seauve et al., 2006; Vesely et al., 2011). Hence, it could be postulated that distinct TADC subsets exert different functions. In first instance, we investigated the antigen uptake, processing and presenting capacities by the three distinct TADC populations.
[0095] Their inherent phagocytic capacity was tested in vitro by adding fluorescent latex beads to 3LL-R tumor single cell suspensions at 37 C. (active phagocytosis) or at 4 C. (
[0096] We next assessed the efficiency of antigen processing by the different TADC subsets. Hereto, 3LL-R tumor single cell suspensions were incubated with DQ-ovalbumin (DQ-OVA) for 15 minutes, allowing antigen uptake. Following thorough washing, intracellular processing was assessed at different time intervals using the fluorescence of cleaved DQ-OVA as readout. No DQ-OVA processing occurred at 0 C. (data not shown). Remarkably, the vast majority of Mo-DC rapidly processed DQ-OVA (62.73.5% of fluorescent cells after 15 min), while no processing had occurred in cDC1 and cDC2 at this early time point (
[0097] Finally, we assessed whether TADC were capable of processing OVA and cross-presenting its immunodominant CTL epitope (SIINFEKL) in vivo, by staining freshly isolated TADC subsets from LLC-OVA tumors with a mAb specific for H-2K.sup.b/SIINFEKL complexes. Mo-DC showed the highest expression of these complexes, indicative of a superior antigen uptake and processing in the tumor microenvironment (
Example 5: Both cDC Populations Activate Naive CD8.SUP.+ and CD4.SUP.+ T Cells, but Only cDC2 Induce a Th17 CD4.SUP.+ T-Cell Phenotype
[0098] We then evaluated the capacity of TADC subsets to activate naive T cells. In this regard, the expression of activating and inhibitory T-cell costimulatory molecules, such as CD80, CD86, PDL1 and PDL2 was very high on all TADC populations (
[0099] To incorporate the effect of a differential in vivo antigen uptake and processing capacity in our assay, TADC were sorted from LLC-OVA tumors and immediately co-cultured with CFSE-labeled TCR transgenic C8.sup.+ OT-I T cells or CD4.sup.+ OT-II T cells without additional ex-vivo Ag-loading or stimulation. At a DC/OT-I ratio of 1/10, only the two cDC subsets could effectively induce CD8.sup.+ T-cell proliferation, hence demonstrating their in vivo immunostimulatory phenotype, whereby the cDC1 were considerably more potent (
Example 6: Mo-DC Display an Immune Suppressive TIP-DC Phenotype
[0100] Tumor-associated Mo-DC were consistently less efficient in activating naive antigen-specific T cells, in spite of their higher antigen uptake and processing capacity. Therefore, we wondered whether the Mo-DC displayed features that could annihilate their T-cell stimulatory functions. We noted that Mo-DC co-expressed high levels of TNF- and iNOS and hence displayed a phenotype reminiscent of inflammatory TIP-DC (
[0101] Importantly, higher iNOS expression might result in a higher NO production, which is reported to be a potential T-cell suppressive molecule (Bronte and Zanovello, 2005; Schouppe et al., 2013). Mo-DC sorted from LLC-OVA tumors were co-cultured with CFSE-labeled CD8.sup.+ OT-I T cells in the presence of the iNOS inhibitor L-NMMA (
Example 7: Both Tumor-Associated cDC Subsets Migrate to Tumor Draining Lymph Nodes and Differentially Activate CD8.SUP.+ and CD4.SUP.+ T Cells
[0102] Tumor-associated cDC possessed T-cell stimulating capacity, so we next wondered whether these cells were capable of migrating to the tumor-draining lymph nodes (tdLN) and present tumor antigen. CCR7 expression, which is a prerequisite for DC migration to LN, was only present on the cDC subsets but not on Mo-DCs (
[0103] In the axillary and inguinal tdLN (draining LN for a subcutaneous tumor in the flank of the animal), cDC1 and cDC2 subsets, but not Mo-DC, were present within the migratory DC population (data not shown), confirming the non-migratory character of Mo-DCs. Migratory and resident DC were discriminated based on CD11c and MHC-II expression, as previously reported (Kissenpfennig et al., 2005; Ohl et al., 2004). To assess whether these cDC present tumor antigen, they were sorted from tdLN of LLC-OVA tumor-bearing mice and co-cultured with CFSE-labeled CD8.sup.+ OT-I T cells or CD4.sup.+ OT-II T cells. Importantly, care was taken that no OVA.sup.+ cancer cells were present in the tdLN at the time of cDC sorting, as illustrated by the absence of OVA mRNA (
Example 8: cDC1 and cDC2 have Both Beneficial but Different Therapeutic Effects when Used for Vaccination
[0104] Finally, to assess whether tumor-derived DC subsets could be used to elicit therapeutically relevant immune memory responses in cancer, we set up vaccination experiments as depicted in
[0105] Remarkably, upon challenge with LLC-OVA, only the cDC2-vaccinated mice had a significantly reduced tumor growth rate and weight compared to the non-vaccinated mice (
[0106] In multiple tumor models, including LLC, tumor growth is not only regulated by TIL, but also by the phenotype of tumor-associated myeloid cells such as myeloid-derived suppressor cells (MDSC) and TAM. Interestingly, the presence of CD11b.sup.hi Ly6C.sup.hi MHC-II.sup.neg Ly6G.sup.neg monocytic cells and CD11b.sup.hi Ly6C.sup.int MHC-II.sup.neg Ly6G.sup.hi granulocytic cells is significantly reduced in tumors of cDC2-vaccinated mice as compared to non-vaccinated and cDC1-vaccinated cohorts (
[0107] Also M2-oriented TAM promote tumor progression. Overall CD11b.sup.hi Ly6C.sup.lo Ly6G.sup.neg TAM numbers only showed a trend towards a reduction in cDC2-vaccinated mice (
[0108] Finally, we turned to the B16-OVA tumor model, in which TAM are present in very low numbers and are mainly M1-like MHC-II.sup.high polarized (
Example 9: The Gating Strategy Applied for Sorting cDC1 and cDC2 Populations from Total 12-Days Old LLC-OVA Tumors Used for the Vaccination Experiments
[0109] Single-cell suspensions were prepared and CD11c.sup.+ cells were MACS-enriched before sorting as described in the experimental procedures. The sorted cDC1 and cDC2 showed very high purities of 94% and 98.5% of the TADC and contained only minor Mo-DC contaminants (0% and 0.7%, respectively,
Example 10: The Therapeutic Effect of TADC Subsets in Tumor Metastasis
[0110] 10.sup.5 LLC-OVA cells are administered in the footpad (a) or 310.sup.6 LLC-OVA cells are administered subcutaneously (b) and grown until a tumor size of about 800 mm.sup.2. The primary tumor is then resected by either leg amputation (a) or subcutaneous tumor removal (b). cDC1 and/or cDC2 populations are isolated from the resected tumor and/or a resected tumor draining lymph node and subsequently injected back into the same individual. Metastatic lung nodules and lung weight are evaluated via microscopy (
TABLE-US-00001 TABLE 1 Antibodies for flow cytometry (FACS). Marker Clone Source 7AAD BD Biosciences B220 Ra3-6B2 BD Biosciences BDCA-1 Biotin AD5-8E7 Miltenyi BDCA-2 PE AC144 Miltenyi CCR2 PE 475301 R&D systems CCR3 PE 83101 R&D systems CCR7 Biotin 4B12 eBioscience CD1d PE 1B1 BD Biosciences CD3 FITC UCHT1 eBioscience CD4 PerCP-Cy5.5/Pe-Cy7/APC RM4-5/GK1.5/RM4-5 BD Biosciences/eBioscience CD8a PE/PE/APC YTS169.4/16-10A1/ Life technologies/eBioscience 53-6.7 CD11b BV605/PerCP-Cy5.5/AF488/ M1/70 BD Biosciences/eBioscience PE-Cy7 CD11c PerCP-Cy5.5/FITC/PE-Cy7/ N418/N418/HL3/3.9/ BD Biosciences/eBioscience PE-Cy7 (anti-human)/PE/APC HL3 CD14 PB TuK4 Invitrogen CD16 PE-TexasRed 3G8 Invitrogen CD19 PE 1D3 BD Biosciences CD19 FITC HIB19 BD Biosciences CD24 PE/PE-Cy7 M1/69 eBioscience CD40 FITC 3/23 BD Biosciences CD45 AF700 (anti-human) HI30 BD Biosciences CD45.1 FITC A20 eBioscience CD45.2 AF700 104 eBioscience CD56 FITC MEM188 eBioscience CD64 PE/APC Y54-5/71 Biolegend CD80 PE 16-10A1 BD Biosciences CD86 PE GI-1 BD Biosciences CD103 biotin M290 BD Biosciences CD127 eFluor450 A7R34 eBioscience CD172a PE/APC P84 BD Biosciences/eBioscience DEC-205 PE 205yekta eBioscience Donkey anti-goat IgG AF647 Polyclonal Invitrogen F4/80 PE/FITC CI;A3-1 Serotec FcR1 Biotin MAR-1 eBioscience Fixable Live/Dead stain eFluor506 / eBioscience Foxp3 PerCP-Cy5.5 FJK-16s eBioscience Gata-3 AF647 TWAJ eBioscience Goat anti-rabbit Polyclonal IgG Life Technologies Goat IgG control biotin Polyclonal goat IgG R&D systems IA/IE PerCP-Cy5.5/APC-eFluor780 M5/114.15.2 Biolegend/eBioscience IFN- APC XMG12 eBioscience iso hamster IgG1, 1 PE G235-2356 BD Biosciences Iso mouse IgG1 k eFluor880 eP3.6 2.8.1 eBioscience Iso Rat IgG1 k PE/APC R3-34/eBRG1 BD Biosciences/eBioscience iso rat IgG2a Biotin/FITC/PE/APC eBR2a/R35-95/R35-95/ BD Biosciences/eBioscience eBR2a iso rat IgG2b, , PE/AF647 A95-1/eB149/10H5 BD Biosciences/eBioscience IRF4 unlabeled M-17 Santa Cruz IRF8 PerCP-Cy5.5 V3GYWCH eBioscience HLA-DR APC-Cy7 LN3 eBioscience KLRG1 APC-eFLuor780 2F1 eBioscience Ly6C AF488/AF647 ER-MP20 Serotec Ly6G FITC/PE 1A8 BD Biosciences MerTK Biotin Polyclonal goat IgG R&D systems MitoSOX Red (MitO2) / Life Technologies NOS2 unlabeled M17 Santa Cruz PD-L1 (B7-H1) PE MIH5 BD Biosciences PD-L2 (B7-DC) PE TY25 eBioscience Rabbit IgG unlabeled Polyclonal rabbit IgG Santa Cruz RORt APC AFKJS-9 eBioscience SiglecF PE E50-2440 BD Biosciences SIINFEKL Biotin eBio25-D1.16 eBioscience SIINFEKL class | MHC dextramer / Immudex APC Streptavidin BV786/PE Streptavidin BD Biosciences T-bet eFluor660 eBio4B10 eBioscience TCRb FITC H57-597 eBioscience TNF- PE MP6-XT22 eBioscience XCR1 PE ZET Biolegend
TABLE-US-00002 TABLE2 PrimersequencesforqRT-PCR.
REFERENCES
[0111] Bosschaerts, T., Morias, Y., Stijlemans, B., Herin, M., Porta, C., Sica, A., Mantovani, A., De Baetselier, P., and Beschin, A. (2011). IL-10 limits production of pathogenic TNF by M1 myeloid cells through induction of nuclear NF-kappaB p50 member in Trypanosoma congolense infection-resistant C57BL/6 mice. Eur J Immunol 41, 3270-3280. [0112] Bronte, V., and Zanovello, P. (2005). Regulation of immune responses by L-arginine metabolism. Nature reviews Immunology 5, 641-654. [0113] Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., to Rosenblum, M. D., Daud, A., Barber, D. L., et al, (2014). Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638-652. [0114] Fridman, W. H., Galon, J., Pages, F., Tartour, E., Sautes-Fridman, C., and Kroemer, G. (2011). Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 71, 5601-5605. [0115] Gabrilovich, D. (2004). Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature reviews Immunology 4, 941-952. [0116] Gao, Y., Nish, S. A., Jiang, R., Hou, L., Licona-Limon, P., Weinstein, J. S., Zhao, H., and Medzhitov, R. (2013). Control of T helper 2 responses by transcription factor IRF4-dependent dendritic cells. Immunity 39, 722-732. [0117] Gautier, E. L., Shay, T., Miller, J., Greter, M., Jakubzick, C., Ivanov, S., Helft, J., Chow, A., Elpek, K. G., Gordonov, S., et al, (2012). Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol 13, 1118-1128. [0118] Goc, J., Germain, C., Vo-Bourgais, T. K., Lupo, A., Klein, C., Knockaert, S., de Chaisemartin, L., Ouakrim, H., Becht, E., Alifano, M., et al, (2014). Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res 74, 705-715. [0119] Greter, M., Helft, J., Chow, A., Hashimoto, D., Mortha, A., Agudo-Cantero, J., Bogunovic, M., Gautier, E. L., Miller, J., Leboeuf, M., et al, (2012). GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity 36, 1031-1046. [0120] Guilliams, M., Ginhoux, F., Jakubzick, C., Naik, S. H., Onai, N., Schraml, B. U., Segura, E., Tussiwand, R., and Yona, S. (2014). Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nature reviews Immunology 14, 571-578. [0121] Guilliams, M., Henri, S., Tamoutounour, S., Ardouin, L., Schwartz-Cornil, I., Dalod, M., and Malissen, B. (2010). From skin dendritic cells to a simplified classification of human and mouse dendritic cell subsets. Eur J Immunol 40, 2089-2094. [0122] Heath, W. R., and Carbone, F. R. (2009). Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol 10, 1237-1244. [0123] Helft, J., Ginhoux, F., Bogunovic, M., and Merad, M. (2010). Origin and functional heterogeneity of non-lymphoid tissue dendritic cells in mice. Immunological reviews 234, 55-75. [0124] Kingston, D., Schmid, M. A., Onai, N., Obata-Onai, A., Baumjohann, D., and Manz, M. G. (2009). The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis. Blood 114, 835-843. [0125] Kissenpfennig, A., Henri, S., Dubois, B., Laplace-Builhe, C., Perrin, P., Romani, N., Tripp, C. H., Douillard, P., Leserman, L., Kaiserlian, D., et al, (2005). Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22, 643-654. [0126] Langlet, C., Tamoutounour, S., Henri, S., Luche, H., Ardouin, L., Gregoire, C., Malissen, B., and Guilliams, M. (2012). CD64 expression distinguishes monocyte-derived and conventional dendritic cells and reveals their distinct role during intramuscular immunization. Journal of immunology 188, 1751-1760. [0127] Laoui, D., Van Overmeire, E., Di Conza, G., Aldeni, C., Keirsse, J., Morias, Y., Movahedi, K., Houbracken, I., Schouppe, E., Elkrim, Y., et al, (2014). Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res 74, 24-30. [0128] Ma, Y., Shurin, G. V., Peiyuan, Z., and Shurin, M. R. (2013). Dendritic cells in the cancer microenvironment. Journal of Cancer 4, 36-44. [0129] Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stange, G., Van den Bossche, J., Mack, M., Pipeleers, D., In't Veld, P., De Baetselier, P., and Van Ginderachter, J. A. (2010). Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 70, 5728-5739. [0130] Ohl, L., Mohaupt, M., Czeloth, N., Hintzen, G., Kiafard, Z., Zwirner, J., Blankenstein, T., Henning, G., and Forster, R. (2004). CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 21, 279-288. [0131] Onai, N., Obata-Onai, A., Schmid, M. A., Ohteki, T., Jarrossay, D., and Manz, M. G. (2007). Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nat Immunol 8, 1207-1216. [0132] Persson, E. K., Uronen-Hansson, H., Semmrich, M., Rivollier, A., Hagerbrand, K., Marsal, J., Gudjonsson, S., Hakansson, U., Reizis, B., Kotarsky, K., and Agace, W. W. (2013). IRF4 transcription-factor-dependent CD103(+)CD11b(+) dendritic cells drive mucosal T helper 17 cell differentiation. Immunity 38, 958-969. [0133] Plantinga, M., Guilliams, M., Vanheerswynghels, M., Deswarte, K., Branco-Madeira, F., Toussaint, W., Vanhoutte, L., Neyt, K., Killeen, N., Malissen, B., et al, (2013). Conventional and monocyte-derived CD11b(+) dendritic cells initiate and maintain T helper 2 cell-mediated immunity to house dust mite allergen. Immunity 38, 322-335. [0134] Preynat-Seauve, O., Schuler, P., Contassot, E., Beermann, F., Huard, B., and French, L. E. (2006). Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. Journal of immunology 176, 61-67. [0135] Remels, L. M., and De Baetselier, P. C. (1987). Characterization of 3LL-tumor variants generated by in vitro macrophage-mediated selection. International journal of cancer Journal international du cancer 39, 343-352. [0136] Schlitzer, A., McGovern, N., Teo, P., Zelante, T., Atarashi, K., Low, D., Ho, A. W., See, P., Shin, A., Wasan, P. S., et al, (2013). IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity 38, 970-983. [0137] Schouppe, E., Mommer, C., Movahedi, K., Laoui, D., Morias, Y., Gysemans, C., Luyckx, A., De Baetselier, P., and Van Ginderachter, J. A. (2013). Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events. Eur J Immunol 43, 2930-2942. [0138] Scott, C. L., Bain, C. C., Wright, P. B., Sichien, D., Kotarsky, K., Persson, E. K., Luda, K., Guilliams, M., Lambrecht, B. N., Agace, W. W., et al, (2015). CCR2(+)CD103() intestinal dendritic cells develop from DC-committed precursors and induce interleukin-17 production by T cells. Mucosal immunology 8, 327-339. [0139] Segura, E., Touzot, M., Bohineust, A., Cappuccio, A., Chiocchia, G., Hosmalin, A., Dalod, M., Soumelis, V., and Amigorena, S. (2013). Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity 38, 336-348. [0140] Serbina, N. V., Jia, T., Hohl, T. M., and Pamer, E. G. (2008). Monocyte-mediated defense against microbial pathogens. Annual review of immunology 26, 421-452. [0141] Steinman, R. M., and Banchereau, J. (2007). Taking dendritic cells into medicine. Nature 449, 419-426. [0142] Tamura, T., Tailor, P., Yamaoka, K., Kong, H. J., Tsujimura, H., O'Shea, J. J., Singh, H., and Ozato, K. (2005). IFN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity. Journal of immunology 174, 2573-2581. [0143] Vesely, M. D., Kershaw, M. H., Schreiber, R. D., and Smyth, M. J. (2011). Natural innate and adaptive immunity to cancer. Annual review of immunology 29, 235-271.